INHIBITORS OF RAF KINASES

1 .- 54 . (canceled)

55 . A compound, or pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of:

(3S)-N-[4-methyl-3-[2-methyl-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-methyl-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-(2-hydroxyethyl)-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-[(2R)-2-hydroxypropyl]-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-[(2R)-1-hydroxypropan-2-yl]-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-[(2S)-2-hydroxypropyl]-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-[(2S)-1-hydroxypropan-2-yl]-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N-(2-hydroxy-2-methylpropyl)-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

(3S)-N-[3-[2-(3-hydroxy-3-methylbut-1-yn-1-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-[2-[(3R)-3-hydroxybut-1-yn-1-yl]-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-[2-[(3R)-3-hydroxybutyl]-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-[2-[(1R,2S)-2-(hydroxymethyl)cyclopropyl]-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(1-methyl-1,2,3-triazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(morpholin-4-yl)-6-(1,3-thiazol-5-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(3-methylimidazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-[2-[(1E,3R)-3-hydroxybut-1-en-1-yl]-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

N-(2-hydroxyethyl)-N-methyl-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

N, N-dimethyl-4-[2-methyl-5-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carbonylamino]phenyl]-6-(morpholin-4-yl)pyridine-2-carboxamide;

(3S)-N-[3-[2-(3-hydroxyazetidine-1-carbonyl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(3-hydroxy-3-methylazetidine-1-carbonyl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-[2-[(1E)-3-hydroxyprop-1-en-1-yl]-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(3-hydroxypropyl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-methoxy-6-(morpholin-4-yl)-[2,4-bipyridin]-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(2-hydroxy-1,3-oxazol-5-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(2-hydroxypropan-2-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(morpholin-4-yl)-6-(piperidin-3-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-(2-[[(2R)-2-hydroxypropyl](methyl)amino]-6-(morpholin-4-yl)pyridin-4-yl)-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-hydroxy-6-(morpholin-4-yl)-[2,4-bipyridin]-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[1′-methyl-6-(morpholin-4-yl)-3′,6′-dihydro-2′H-[2,4′-bipyridin]-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(2-hydroxyethyl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(morpholin-4-yl)-6-(1H-pyrazol-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(4-methyl-3-(2-morpholino-6-(pyrrolidin-3-yl)pyridin-4-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(1-methyl-2,5-dihydropyrrol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(1-methylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(1,3-dimethylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(4-methyl-3-(2-(1-methylpyrrolidin-3-yl)-6-morpholinopyridin-4-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(S)-N-(4-methyl-3-(2-(1-methylpiperidin-4-yl)-6-morpholinopyridin-4-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2′-amino-6-(morpholin-4-yl)-[2,4′-bipyridin]-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-[2-[1-(difluoromethyl)pyrazol-4-yl]-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(morpholin-4-yl)-6-(1,3-thiazol-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(2-amino-3H-imidazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(5-amino-1-methylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(2-aminopyrimidin-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2′-(difluoromethyl)-6-(morpholin-4-yl)-[2,4′-bipyridin]-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(3-methyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(1,5-dimethylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(2-methylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(2,5-dimethylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(3,5-dimethyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(1,5-dimethylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(1H-imidazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{4-methyl-3-[2-(1-methylimidazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{3-[2-(3-aminobut-1-yn-1-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[4-methyl-3-[2-(morpholin-4-yl)-6-(trifluoromethyl)pyridin-4-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{3-[2-(difluoromethyl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-(2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-(3-{2-[2-(2-hydroxyethyl)pyrazol-3-yl]-6-(morpholin-4-yl)pyridin-4-yl}-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-[3-[2-(hydroxymethyl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{4-methyl-3-[2-(4-methyl-1,2,4-triazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(2S)-N-{4-methyl-3-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-2-(trifluoromethyl)morpholine-4-carboxamide;

(2R)-N-{4-methyl-3-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-2-(trifluoromethyl)morpholine-4-carboxamide;

(3R)-N-{4-methyl-3-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethoxy)pyrrolidine-1-carboxamide;

(2R)-N-{4-methyl-3-[2-(2-methylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-2-(trifluoromethyl)morpholine-4-carboxamide;

N-{4-methyl-3-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)-2,5-dihydropyrrole-1-carboxamide;

(2S)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-2-(trifluoromethyl)morpholine-4-carboxamide;

(2R)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-2-(trifluoromethyl)morpholine-4-carboxamide;

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)-2,5-dihydropyrrole-1-carboxamide;

(3S)-N-{2-fluoro-4-methyl-5-[2-methyl-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{5-[2-cyclopropyl-6-(morpholin-4-yl)pyridin-4-yl]-2-fluoro-4-methylphenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{5-[2-ethyl-6-(morpholin-4-yl)pyridin-4-yl]-2-fluoro-4-methylphenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

N-{2-fluoro-4-methyl-5-[2-(2-methylpyrazol-3-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)-2,5-dihydropyrrole-1-carboxamide;

(3S)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

(3R)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)pyrrolidine-1-carboxamide;

(3S)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)pyrrolidine-1-carboxamide;

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxamide;

(3S)-N-{3-[2-(1-ethylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(1,1,2,2,2-pentafluoroethyl)-2,5-dihydropyrrole-1-carboxamide;

(3R)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(1,1,2,2,2-pentafluoroethyl)pyrrolidine-1-carboxamide;

(3S)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(1,1,2,2,2-pentafluoroethyl)pyrrolidine-1-carboxamide;

(3S)-3-tert-butyl-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}pyrrolidine-1-carboxamide;

(3R)-3-tert-butyl-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}pyrrolidine-1-carboxamide;

(3R)-3-(1,1-difluoroethyl)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}pyrrolidine-1-carboxamide; and

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2-fluoropropan-2-yl)pyrrolidine-1-carboxamide.

56 . The compound, or pharmaceutically acceptable salt or solvate thereof, of claim 55 having the structure of:

(3S)-N-[3-[2-(1H-imidazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.

57 . The compound, or pharmaceutically acceptable salt or solvate thereof, of claim 55 having the structure of:

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)-2,5-dihydropyrrole-1-carboxamide.

58 . The compound, or pharmaceutically acceptable salt or solvate thereof, of claim 55 having the structure of:

(3S)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.

59 . The compound, or pharmaceutically acceptable salt or solvate thereof, of claim 55 having the structure of:

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxamide.

60 . The compound, or pharmaceutically acceptable salt or solvate thereof, of claim 55 having the structure of:

N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2-fluoropropan-2-yl)pyrrolidine-1-carboxamide.

61 . A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, as described in claim 55 and a pharmaceutically acceptable excipient.

62 . The pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, as described in claim 61 and a pharmaceutically acceptable excipient, wherein the compound is (3S)-N-[3-[2-(1H-imidazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.

63 . The pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, as described in claim 61 and a pharmaceutically acceptable excipient, wherein the compound is N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(trifluoromethyl)-2,5-dihydropyrrole-1-carboxamide

64 . The pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, as described in claim 61 and a pharmaceutically acceptable excipient, wherein the compound is (3S)-N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.

65 . The pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, as described in claim 61 and a pharmaceutically acceptable excipient, wherein the compound is N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxamide.

66 . The pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, as described in claim 61 and a pharmaceutically acceptable excipient, wherein the compound is N-{2-fluoro-4-methyl-5-[2-(1-methylpyrazol-4-yl)-6-(morpholin-4-yl)pyridin-4-yl]phenyl}-3-(2-fluoropropan-2-yl)pyrrolidine-1-carboxamide.